Compare ORIC & KRSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORIC | KRSA |
|---|---|---|
| Founded | 2014 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2020 | 2019 |
| Metric | ORIC | KRSA |
|---|---|---|
| Price | $7.61 | $32.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 6 |
| Target Price | $21.79 | ★ $44.00 |
| AVG Volume (30 Days) | ★ 1.8M | 167.5K |
| Earning Date | 11-16-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.67 | 8.26 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,074,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 3.70 |
| 52 Week Low | $7.23 | $29.03 |
| 52 Week High | $14.68 | $37.27 |
| Indicator | ORIC | KRSA |
|---|---|---|
| Relative Strength Index (RSI) | 30.56 | 51.99 |
| Support Level | $7.40 | $29.67 |
| Resistance Level | $14.23 | $34.51 |
| Average True Range (ATR) | 0.70 | 1.87 |
| MACD | -0.10 | 0.21 |
| Stochastic Oscillator | 1.97 | 62.45 |
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
Korsana Biosciences Inc is a biopharmaceutical company developing therapeutics to treat neurodegenerative diseases beginning with Alzheimer's disease (AD. The company's flagship product candidate, KRSA-028, is an anti-amyloid beta antibody that combines the proprietary Therapeutic Targeting (THETA) platform with well-validated aspects from other anti-Ab products that have achieved regulatory approval or are in late-stage clinical trials.